



26 January 2021

**OMEGA DIAGNOSTICS GROUP PLC**  
**("Omega" or the "Company" or the "Group")**

**Update re AbC-19™ Rapid Test &**  
***Launch of COVID-19 antibody laboratory-based testing service***

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes today's update from Abingdon Health plc (AIM: ABDX) ("Abingdon Health") regarding the AbC-19™ Rapid Test, confirming their expectations for future supply arrangements with the Department of Health and Social Care, the ongoing efforts to obtain regulatory approvals in a total of 27 geographies, and the ongoing work to build data the set(s) around the use-case for the AbC-19™ Rapid Test alongside vaccines.

In addition, Omega will today announce the launch of its COVID-19 antibody lab-based testing service in Littleport, Cambridgeshire (see separate RNS Reach for details), using the Mologic ELISA<sup>1</sup> antibody test. This service will be offered to commercial occupational health partners, clinics and health care professionals in the UK.

**Colin King, CEO of Omega Diagnostics, said:** *"We welcome the update from Abingdon Health this morning and look forward to being able to update investors on the potential to open up significant commercial opportunities outside of the UK in due course."*

<sup>1</sup>ELISA (Enzyme Linked Immuno-Sorbent Assay)

**Contacts:**

**Omega Diagnostics Group PLC**

Bill Rhodes, Interim Non-Executive Chairman  
Colin King, Chief Executive  
Kieron Harbinson, Group Finance Director

Tel: 01259 763 030  
[www.omegadiagnostics.com](http://www.omegadiagnostics.com)

**finnCap Ltd**

Geoff Nash/Edward Whiley (Corporate Finance)  
Alice Lane (ECM)

Tel: 020 7220 0500

**Walbrook PR Limited**

Paul McManus  
Lianne Cawthorne

Tel: 020 7933 8780 or [omega@walbrookpr.com](mailto:omega@walbrookpr.com)  
Mob: 07980 541 893  
Mob: 07584 391 303